Life Science News

FDA clearance expands use of the INVOS™ 7100 system, helping clinicians better monitor organ-specific oxygen levels and identify warnings signs for neonates and children earlier

- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its INVOS™ 7100 cerebralsomatic oximetry system for children from birth through age 18. The INVOS system picks up key signals to inform time-critical decisions by pediatric clinicians related to hemodynamic management, ventilation, and resuscitation for premature infants, neonates, children, and other patients treated by pediatric clinicians.

"Timing is critical for vulnerable pediatric patients, and the INVOS™ 7100 system can alert clinicians to changes in patient condition before traditional monitored parameters even react," 1, 2 said Frank Chan , president of the Patient Monitoring business, which is part of the Medical Surgical Portfolio at Medtronic. "The INVOS™ 7100 system can help clinicians decide if intervention is necessary — a core component in successful outcomes. And our technology consistently enables users to determine if they need to intervene sooner." 1-6

The INVOS™ near-infrared spectroscopy monitoring system has been previously cleared for use in adult patients and is the clinical reference standard for regional oximetry. 7 The real-time measures of tissue perfusion and oxygenation provided by the INVOS™ 7100 system provide early alerts to changes in perfusion before other vital sign measurements. 1, 2 This data may indicate to clinicians that a patient is becoming critical — providing them the crucial time needed to treat newborns and young patients.

"There are so many time-critical conditions clinicians face when treating some of our youngest patients in intensive care units, from RSV to complex heart conditions and beyond. We see this as an opportunity to equip providers with technology that can help improve outcomes among the most vulnerable populations," said Sam Ajizian , MD, FAAP, FCCM, CPPS, and chief medical officer of the Patient Monitoring business at Medtronic. "We are thrilled that the INVOS™ 7100 system has been cleared for pediatric indications."

The technology inside the INVOS™ 7100 system delivers first-alert performance with its unique algorithms that measure acute alterations in hemodynamics, regional oxygen saturation, and oxygen metabolism. 1, 2 The system provides continuous, noninvasive readings of organ-specific regional blood oxygen levels in up to four site specific areas chosen by the care team and oxygen saturation from vascular beds to assess organs individually, or in combination to track brain/body perfusion shifts.

The INVOS™ 7100 system with the pediatric indications will be available worldwide for commercial use in spring 2022.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland , is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people across 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE:MDT), visit www.Medtronic.com and follow @Medtronic on Twitter and LinkedIn .

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

The INVOS™ monitoring system should not be used as the sole basis for diagnosis or therapy and is intended only as an adjunct in patient assessment.

1.

Lu Y, Di M, Li C, Chen M, Yuan K, Shangguan W. Comparing the response of pulse oximetry and regional cerebral oxygen saturation to hypoxia in preschool children. Exp Ther Med . Jan 2020;19(1):353-358. doi:10.3892/etm.2019.8199

2.

Tobias JD. Cerebral oximetry monitoring with near infrared spectroscopy detects alterations in oxygenation before pulse oximetry. J Intensive Care Med . Nov-Dec 2008;23(6):384-8. doi:10.1177/0885066608324380

3.

Alderliesten T, Lemmers PM, van Haastert IC, et al. Hypotension in preterm neonates: low blood pressure alone does not affect neurodevelopmental outcome. J Pediatr . May 2014;164(5):986-91. doi:10.1016/j.jpeds.2013.12.042

4.

Bonestroo HJ, Lemmers PM, Baerts W, van Bel F. Effect of antihypotensive treatment on cerebral oxygenation of preterm infants without PDA. Pediatrics . Dec 2011;128(6):e1502-10. doi:10.1542/peds.2010-3791

5.

Chock VY, Kwon SH, Ambalavanan N, et al. Cerebral Oxygenation and Autoregulation in Preterm Infants (Early NIRS Study). J Pediatr . Dec 2020;227:94-100.e1. doi:10.1016/j.jpeds.2020.08.036

6.

Pichler G, Urlesberger B, Baik N, et al. Cerebral Oxygen Saturation to Guide Oxygen Delivery in Preterm Neonates for the Immediate Transition after Birth: A 2-Center Randomized Controlled Pilot Feasibility Trial. J Pediatr . Mar 2016;170:73-8.e1-4. doi:10.1016/j.jpeds.2015.11.053

7.

Yu Y, Zhang K, Zhang L, Zong H, Meng L, Han R. Cerebral near-infrared spectroscopy (NIRS) for perioperative monitoring of brain oxygenation in children and adults. Cochrane Database Syst Rev . Jan 17 2018;1(1):Cd010947. doi:10.1002/14651858.CD010947.pub2

Contacts:




Ellen Lupfer

Ryan Weispfenning

Public Relations

Investor Relations

+1-508-212-9845

+1- 763-505-4626

View original content to download multimedia: https://www.prnewswire.com/news-releases/medtronic-invos-7100-cerebralsomatic-oximetry-system-receives-510k-clearance-for-pediatric-indications-301443601.html

SOURCE Medtronic plc

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/December2021/14/c5360.html

News Provided by Canada Newswire via QuoteMedia

Abbott Enters into Consent Decree with U.S. Food and Drug Administration for its Sturgis, Mich., Plant; Agreement Creates Pathway to Reopen Facility

  • After FDA approval, Abbott could restart the site within two weeks; from the time of restart it would take six to eight weeks before product is available on shelves
  • Abbott will continue to import formula from FDA-registered facility in Ireland to help alleviate near-term supply shortage
  • CDC concluded its investigation with no findings of a link between Abbott formulas and infant illnesses

Abbott (NYSE: ABT) has agreed to enter into a consent decree with the U.S. Food and Drug Administration (FDA) related to its Sturgis, Mich. infant formula plant. The decree is an agreement between FDA and Abbott on the steps necessary to resume production and maintain the facility. This does not affect any other Abbott plant or operation. The decree is subject to court approval.

"Our number one priority is getting infants and families the high-quality formulas they need, and this is a major step toward re-opening our Sturgis facility so we can ease the nationwide formula shortage. We look forward to working with the FDA to quickly and safely re-open the facility," said Robert B. Ford , chairman and chief executive officer, Abbott. "We know millions of parents and caregivers depend on us and we're deeply sorry that our voluntary recall worsened the nationwide formula shortage. We will work hard to re-earn the trust that moms, dads and caregivers have placed in our formulas for more than 50 years."

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Viemed Provides Update Concerning Successful Appeal of Office of Inspector General Findings

Viemed Healthcare, Inc. (the " Company " or " Viemed ") (NASDAQ:VMD and TSX:VMD.TO), a home medical equipment supplier and the nation's largest independent provider of ventilation that provides post-acute respiratory care services, is providing an update concerning the Company's appeal of claims related to findings from the U.S. Department of Health and Human Services Office of Inspector General ("OIG") in a May 2021 report ("Report"). Based on an objective and independent review of patients' medical records, the Centers for Medicare and Medicaid Services' ("CMS") Qualified Independent Contractor ("QIC") responsible for evaluating the Company's Reconsideration appeals determined that approximately 77% of the claims it reviewed were medically necessary and properly payable under Medicare rules and regulations, overturning OIG's and CMS's initial recommendations and determinations.

"The success of our latest round of appeals is an extremely positive development for patients and their families who depend on payors to hold up their end of the health care delivery network," said Casey Hoyt, Viemed's CEO. "We wholeheartedly believe in protecting and advancing the rights of these patients to have access to the care prescribed by qualified licensed physicians. As a leader in the respiratory care industry, we will continue to support responsible rulemaking and other initiatives to ensure that the best care remains available to those in need."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Applied UV Announces Order for The Renaissance Cleveland Hotel

Applied UV Announces Order for The Renaissance Cleveland Hotel

$2M Furnishings Order Expected Subject to Initial "Model Room" Product Approval

Applied UV, Inc. (NasdaqCM: AUVI ) ("Applied UV" or the "Company"), a pathogen elimination technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, announces that its wholly owned subsidiary MunnWorks, a custom manufacturer of luxury mirrors and furniture for the hospitality market, has received a model room order from The Renaissance Cleveland Hotel , which will be fully funded by the developer of the hotel. Upon successful acceptance of the "Model Room" order, a follow-on $2M order is expected. This order for hotel furniture will be manufactured in MunnWorks 100,000 square foot Brooklyn, NY manufacturing facility, which MunnWorks acquired on March 31 st , 2022, through the purchase of VisionMark LLC's luxury furniture manufacturing business.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Medtronic receives FDA approval for latest generation drug-eluting coronary stent system

The Onyx Frontier™ drug-eluting stent offers an innovative delivery system and builds upon the acute performance and clinical data from the Resolute Onyx™ drug-eluting stent

Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it received U.S. Food and Drug Administration (FDA) approval for the Onyx Frontier™ drug-eluting stent (DES). As the latest evolution in the Resolute DES family, Onyx Frontier DES leverages the same best-in-class stent platform as Resolute Onyx™ DES, with an enhanced delivery system 1 designed to improve deliverability and increase acute performance 2 in even the most challenging of cases. 1

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Medtronic completes acquisition of Intersect ENT

Acquisition adds innovative bioabsorbable steroid-eluting sinus implants to ENT portfolio

- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it has completed the acquisition of Intersect ENT, expanding the company's comprehensive ear, nose, and throat (ENT) portfolio with innovative products used in sinus procedures to improve post-operative outcomes and to treat nasal polyps.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Danaher Joins Bespoke Gene Therapy Consortium for Rare Diseases

Consortium aims to speed the development and delivery of customized or 'bespoke' gene therapies

Danaher Corporation (NYSE: DHR) announced that it has joined the Bespoke Gene Therapy Consortium (BGTC). Launched in October 2021 the BGTC will generate gene therapy resources that the research community can use to streamline gene therapy development for rare disorders, making the process more efficient and less costly. Danaher's Life Science companies join the Food and Drug Administration (FDA), the National Institutes of Health (NIH), twelve pharmaceutical and biotech companies and nine non-profits, and will be represented by experts from Danaher Corporation and its companies, notably Pall Corporation, Aldevron and Cytiva. The project is managed by the Foundation for the National Institutes of Health (FNIH) as part of the Accelerating Medicines Partnership® program.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×